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Abstract 
 
Liver fibrosis and cirrhosis resulting from long-standing liver damage represents a major 
health care burden worldwide. To date, there is no anti-fibrogenic agent available, making 
liver transplantation the only curative treatment for decompensated cirrhotic liver disease. 
Liver fibrosis can result from different underlying chronic liver disease, such as chronic viral 
infection, excessive alcohol consumption, fatty liver disease or autoimmune liver diseases. It 
is becoming increasingly recognised that as a result from different pathogenic mechanisms 
liver fibrosis must be considered as many different diseases for which individual treatment 
strategies need to be developed. Moreover, the pathogenic changes of both liver architecture 
and vascularisation in cirrhotic livers, as well as the lack of “true-to-life” in vitro models have 
impeded the development of an effective anti-fibrogenic drug. Thus, in order to identify an 
efficient anti-fibrogenic compound, novel in-vitro models mimicking the interplay between 
pro-fibrogenic cell populations, immune cells and, importantly, the extracellular matrix need 
to be developed. 
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1. General aspects/ introduction 
 
Liver fibrosis is a chronic liver condition that develops as a result of a chronic wound healing 
response following long-standing liver injury. During hepatic fibrogenesis, the liver 
parenchyma undergoes fundamental remodelling characterized by progressive accumulation 
of fibrillar extracellular matrix (ECM) associated with nodular regeneration of the liver 
parenchyma. If untreated, liver fibrosis develops into cirrhosis and results in progressive loss 
of the normal liver function, which can lead to liver failure and death [1, 2].  
In Europe, liver cirrhosis is the fourth most common cause of death with a prevalence of 76.3 
per 100,000 aged over 25 in 2001 in the United Kingdom, and is more likely to occur in men 
[3]. The development of liver cirrhosis is driven by several different risk factors, the frequency 
of which varies regionally. Thus, in western countries excessive alcohol consumption, 
hepatitis C virus (HCV) infection and fatty liver disease are most common, whereas chronic 
hepatitis B virus (HBV) infection is the main risk factor in Asia [4, 5]. Furthermore, liver 
cirrhosis can evolve from a chronic immune-mediated damage in the context of autoimmune 
liver disease (AILD), such as primary sclerosing cholangitis (PSC), primary biliary cholangitis 
(PBC) and autoimmune hepatitis (AIH) [6-8]. Other less common risk factors include Wilson’s 
disease (copper overload), haemochromatosis (iron overload) and 1-antitrypsin deficiency, 
while some cases are cryptogenic [9, 10].  
Although liver fibrosis has historically been considered as one disease, it has become clear 
that the pathophysiology of liver cirrhosis varies depending on the underlying aetiology, 
which has not only changed the perception of liver cirrhosis, but also created new challenges 
in treating cirrhosis. 
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Preventing the progression to cirrhosis and even attempting a regression of the fibrogenic 
process is based on treating the underlying cause of disease, as the progression of liver 
fibrosis, and even cirrhosis, can be attenuated when the harmful agent or stimulus is removed 
[11, 12]. Hence, antiviral treatment in HCV and HBV infection, immunosuppression in 
autoimmune hepatitis, abstinence from alcohol in alcoholic liver disease, weight loss and 
lifestyle change in fatty liver disease, venesection for haemochromatosis and copper 
chelating agents or zinc in Wilson’s disease have been established as means to stabilize and 
possibly even reverse disease progression [10, 13-15]. Nevertheless, the possibility of 
approaching established fibrosis and even cirrhosis with an effective anti-fibrotic strategy 
would immensely change the prognosis and the overall management of patients with 
advanced liver fibrosis and cirrhosis. For this reason, extensive investments have been made 
in the past 20-30 years for the development of anti-fibrotic drugs exploring different 
therapeutic approaches and routes of drug delivery. 
Importantly, despite the deeper knowledge of the pathophysiology and advances in treating 
liver cirrhosis, this condition still represents the main indication for over 5000 liver 
transplantations in Europe per year [4, 10], which is the only curative treatment for end-stage, 
decompensated liver cirrhosis at present. This is further aggravated by the fact that liver 
transplantation is not eligible to all cirrhotic patients and there is a severe lack of donor 
organs, stressing the need for novel and high impact therapeutic strategies. This article 
summarises the current knowledge on the mechanisms of liver fibrogenesis and attempts an 
analysis on the methodological barriers to the development of anti-fibrotic agents to be 
tested in preclinical studies.  
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2. Hepatic Fibrogenesis: general mechanisms 
 
The development of liver fibrosis and subsequent cirrhosis is driven by ongoing liver injury 
through multiple mechanisms, and can be considered as an excessive wound healing 
response fuelled by a pathogenic vicious circle of hepatocyte necrosis, inflammation and 
excessive ECM deposition [1, 16]. Progression from healthy liver tissue to cirrhosis occurs 
after approximately 15-20 years of chronic hepatocellular damage [16], by when the cirrhotic 
liver contains up to six times more ECM than a normal liver [13]. Long-term chronic exposure 
to toxic agents such as hepatitis viruses, alcohol or bile acids can induce hepatocyte damage 
and apoptosis. In response, a repair reaction is triggered, which is characterized by ECM 
deposition and inflammation and results in liver fibrosis, when not only the exposure to toxic 
agents, but also the repair reaction is chronic [1]. The main ECM producing cell type in the 
liver are hepatic stellate cells (HSCs) which develop into hyper proliferative, ECM secreting 
myofibroblasts upon activation [1, 17].  Although HSCs are the main source of myofibroblasts 
in the liver [18, 19], other cell types contribute to the pool of fibrogenic myofibroblasts in liver 
disease. Portal myofibroblasts are located around bile ducts and play a role for the 
development of biliary fibrosis [20, 21]. Moreover, bone marrow derived myofibroblasts are 
thought to contribute to the development of liver fibrosis [22], although their contribution in 
murine fibrosis has shown to be minimal [23]. 
Activation of HSCs is stimulated by damaged and apoptotic hepatocytes through two main 
routes: release of damage-associated reactive oxygen species (ROS) and other fibrogenic 
mediators [24, 25] and recruitment of immune cells, which in turn mediate HSC activation 
and stimulate collagen secretion through release of cytokines and chemokines [26, 27]. 
Following the initial activation of HSCs, cytokines secreted by HSCs in an autocrine manner, 
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as well as immune cell derived cytokines, provide signals that maintain HSC activation and 
survival and the associated ECM deposition [17]. As a result, a vicious circle emerges, in which 
mutual stimulation between inflammatory and pro-fibrogenic cells drives hepatic 
fibrogenesis [28, 29].  
Besides affecting the quantity of ECM, liver fibrosis also results in changes in the quality and 
topographic distribution of different ECM components. In the healthy liver, the ECM in the 
space of Disse, the space between endothelial cells and hepatocytes, mainly consists of 
collagen IV and VI. During fibrosis development, ECM is replaced by fibrillary collagens, such 
as collagen I and III, as well as fibronectin, leading to so-called capillarization of the sinusoids 
[30]. When fibrosis is established and chronic liver diseases has evolved from fibrosis to 
cirrhosis, major structural changes including extensive capillarisation of the liver sinusoids and 
formation of intrahepatic vascular shunts, as well as functional abnormalities, such as 
endothelial dysfunction, occur. Endothelial dysfunction results from decreased endothelial 
synthesis of vasodilators, such as nitric oxide, as well as increased secretion of 
vasoconstrictors, such as thromboxane A2 and endothelin [31, 32]. 
Such structural and functional changes result in the development of portal hypertension (PH), 
the major complication of liver cirrhosis, which in turn gives rise to other clinically relevant 
complications of cirrhosis, including ascites, variceal bleeding, hepatic encephalopathy and 
renal failure [1, 10]. Moreover, liver cirrhosis is the major risk factor for the development of 
hepatocellular carcinoma (HCC), as more than 80% of HCCs develop on a fibrotic or cirrhotic 
background [16, 33]. The high risk of HCC development represents a major healthcare issue, 
as HCC is the fifth most common solid tumour and the second leading cause for cancer deaths 
worldwide with a rising incidence in Europe and the United States of America [34, 35]. 
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3. Cirrhosis or Cirrhoses? 
 
Liver fibrosis can result from many different conditions, in which liver damage shows 
characteristic patterns of injury [2]. Along these lines, liver fibrosis shows different 
morphological patterns according to the underlying aetiology. Thus, viral hepatitis is 
associated with interface hepatitis and portal-central vein bridging fibrosis, whereas alcoholic 
fibrosis and non-alcoholic steatohepatitis (NASH) are characterized by perisinusoidal or 
pericellular fibrosis showing a so-called chicken wire pattern. In biliary cirrhosis, bile duct and 
portal myofibroblast proliferation result in the formation of portal-portal fibrotic septa [2, 36, 
37]. Moreover, some pathophysiological mechanisms contributing to hepatic fibrogenesis are 
distinct between different aetiologies, whereas other mechanisms are shared across 
aetiologies, highlighting the need of individual concepts for the therapy of liver fibrosis and 
cirrhosis. 
 
3.1 Alcoholic liver disease (ALD)  
 
Resulting from long-standing excessive alcohol consumption, ALD can range from hepatic 
steatosis to acute alcoholic hepatitis to the development of liver fibrosis and cirrhosis on the 
basis of which HCC can develop [38]. Fibrosis development in ALD is driven by hepatocyte 
apoptosis and formation of ROS induced by the toxic effect of ethanol and its metabolite 
acetaldehyde [39, 40]. Moreover, several mechanisms specific to excessive alcohol intake 
stimulate HSC activation and thereby drive ECM deposition and inflammation. Thus, 
acetaldehyde can directly activate HSCs and stimulate collagen I expression [41]. 
Furthermore, bacteria derived lipopolysaccharide (LPS), which is translocated from the gut to 
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the liver due to increased gut permeability in ALD [42], can stimulate HSC activation directly 
via Toll-like-receptor (TLR) 4 ligation [43, 44]. Along these lines, LPS acts indirectly on HSC 
activation via stimulation of Kupffer cells, which in turn secrete HSC activating cytokines [45]. 
Ethanol furthermore inhibits the function of natural killer (NK) cells, which can contribute to 
fibrosis resolution through IFN secretion and killing of activated HSCs, thereby suppressing 
the anti-fibrotic effects of NK cells [46]. 
 
3.2 NAFLD/NASH 
 
Non-alcoholic fatty liver disease (NAFLD) and its more severe form NASH occur in the context 
of the metabolic syndrome and are characterized by hepatic steatosis which can lead to the 
development of fibrosis and cirrhosis over time [47]. The formation of ROS and resulting 
oxidative stress induced by a mitochondrial overflow of free fatty acids is thought to be a 
critical factor in fibrosis development in NAFLD/NASH though several pathways. Oxidative 
stress hinders the replication of mature hepatocytes, thus leading to an accumulation of 
immature progenitor cells [48] originating from the Canals of Hering. Proliferation of such 
progenitor cells results in the formation of small ductules. This so-called ductular reaction has 
been linked to the development of fibrosis in NAFLD/NASH as the newly formed ductular cells 
secrete pro-inflammatory cytokines [49], and epithelial-mesenchymal transition of 
cholangiocytes to fibrogenic myofibroblasts can occur [50]. Moreover, hepatic steatosis is 
accompanied by an inflammatory reaction with elevated levels of pro-inflammatory cytokines 
such as IL-1, IL-6 and TNF, mediated by activation of the INF-B signalling pathway 
in the liver [51]. Free fatty acids can directly activate the INF-B signalling pathway in 
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hepatocytes [52] and it has been shown that cytokine production by hepatocytes is a critical 
factor for the progression of steatosis to NASH [53]. 
 
3.3 Viral hepatitis 
 
Both HBV and HCV are non-cytopathic viruses, thus liver damage is mediated by the host’s 
immune system attempting to clear the virus [54]. However, virus-specific T cell typically 
become exhausted in viral hepatitis [55, 56], and are therefore unable to eliminate the virus, 
leading to chronic infection and inflammation which results in liver damage and fibrosis 
development [57]. As such exhausted virus-specific T cells are unable to mediate liver 
damage, necroinflammation in viral hepatitis is driven by secondary recruitment of 
mononuclear cells [58]. Moreover, some HCV proteins are able to stimulate the activation of 
pro-fibrogenic and pro-inflammatory properties of HSCs, thereby directly contributing to 
fibrogenesis [59]. In hepatocytes, HCV proteins induce the production of ROS and subsequent 
oxidative stress. Such ROS are thought to contribute to fibrogenesis both through direct 
damaging effects on hepatocytes and other cell types, as wells as by activation of hepatic 
stellate cells [60]. 
 
 
3.4 Autoimmune liver diseases  
 
Autoimmune liver diseases (AILD) such as AIH, PBC and PSC are characterized by chronic 
inflammation which plays a pathogenic role for the development of fibrosis in these diseases. 
Immunologically, a loss of self-tolerance leads to autoimmune cell damage, and hepatic 
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inflammation is aggravated by aberrant recruitment of immune cells to the liver, as well as by 
an altered balance in both immune regulation and the response to foreign and self antigens 
[6, 61]. In the cholestatic autoimmune liver diseases PSC and PBC, intrahepatic accumulation 
of bile acids contributes to fibrogenesis through induction of hepatocyte and cholangiocyte 
apoptosis and necrosis [6, 62], as well as through activation of the bile acid/farnesoid X 
receptor (FXR). It has been demonstrated that a lack of FXR specifically inhibits cholestatic 
fibrogenesis [63], proposing the FXR axis as a novel therapeutic target in AILD. Moreover, it 
has been demonstrated that cholangiocytes play a role for fibrosis development in 
cholangiopathies. In particular, the cross-talk between proliferating cholangiocytes and portal 
fibroblasts, which are contributing to fibrosis development in PSC and PBC, has been 
highlighted as critical for fibrogenesis. Thus, cholangiocytes secrete a vast number of pro-
fibrogenic effectors including pro-proliferative cytokines, chemokines and growth factors, 
which show an activating effect on portal myofibroblasts [64].  
 
3.5 Aetiology-driven patterns of liver fibrosis development  
 
Although cirrhosis is the common result of progressive fibrogenesis, there are distinct 
patterns of fibrotic development, related to the underlying disorders causing the fibrosis and 
depending on the origin of fibrogenic cells [2]. Biliary fibrosis, characterized by the co-
proliferation of reactive bile ductules and periductular myofibroblast-like cells at the portal-
parenchymal interface, tends to follow a portal to portal direction with the consequent 
formation of portal-portal septa surrounding liver nodules, where the central vein and its 
connections with the portal tract are preserved until late stages. In contrast, the chronic viral 
hepatitis characterized by portal-central (vein) bridging necrosis leads to the formation of 
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portal-central septa and to the rapid derangement of the vascular connections with the portal 
system (early portal hypertension). The so-called central to central (vein) form of fibrogenic 
evolution is in general secondary to venous outflow problems (e.g. chronic heart failure) and 
is characterized by the development of central to central septa and “reversed lobulation”. 
Finally, pericellular/perisinusoidal fibrosis is observed in alcoholic and metabolic liver diseases 
(e.g. NASH), in which the deposition of fibrillar matrix is concentrated around the sinusoids 
(capillarization) and around groups of hepatocytes (chicken-wire pattern).  These different 
patterns of fibrogenic evolution are related to different factors and particularly: 1. the 
topographic localization of tissue damage, 2. the relative concentration of pro-fibrogenic 
factors, 3. the prevalent pro-fibrogenic mechanism(s) and 4. the origin of the pro-fibrogenic 
myofibroblast. In addition, these different patterns imply the participation of different cellular 
effectors of the fibrogenic process. 
These striking differences in the development of liver fibrosis and the relative prevalent 
mechanisms typical of chronic liver diseases caused by different aetiologies represent a 
crucial issue when discussing the features of the proposed anti-fibrotic treatments and the 
development of biomarkers to be employed alongside the treatment to monitor its 
effectiveness.   
 
4. Chronic liver diseases:  the actual need for anti-fibrotic strategies 
 
At present, no drugs with the specific indication “anti-fibrotic” are available in spite of over 
30 years of active research in this field. To date, specific therapies for liver disease have 
primarily been aetiology-driven by eliminating or ameliorating the causative agent of chronic 
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liver disease (CLD). Recent examples include the introduction of anti-viral agents for hepatitis 
B and C virus infections, which have been fruitful in blocking chronic liver injury and thus 
progression of fibrosis, and even in reversing advanced fibrosis. Overall, the increasing 
success of antiviral treatments in blocking or reversing the fibrogenic progression of CLD has 
provided vital information about the natural history of fibrosis regression, and has established 
important principles and targets for anti-fibrotic drugs at least concerning fibrogenic 
disorders of the liver [65].   It is important to stress that despite the documented evidence of 
fibrosis and cirrhosis regression in animal models and the reabsorption of scar tissue following 
an effective causative treatment, the full reversibility of fibrosis in patients with advanced 
fibrosis and cirrhosis is still debated [66, 67].   
Besides the obvious advantage of employing anti-fibrotic agents in CLD where there is no 
effective causative pharmacological treatment (basically all CLD with the exclusion of chronic 
HBV and HCV and to a certain extent autoimmune hepatitis), the use of anti-fibrotic agents 
would be particularly advantageous in CLD where the cause of damage has been eliminated 
only in a very advanced phase of the disease. This situation is typically represented by the 
elimination of HCV (sustained viral response, SVR) in patients with compensated or 
decompensated cirrhosis. Indeed, a key lesson emerging from several recent studies is that 
in compensated cirrhotic patients with clinically significant and severe PH, HCV clearance does 
not induce a significant reduction of PH and that cirrhosis, once advanced, may progress to 
decompensation even in absence of HCV replication. In biological terms, this can be explained 
by the relative autonomy acquired by the fibrogenic process beyond a certain level of 
development over decades, which is characterised by chronic fibro-inflammation and neo-
angiogenesis. In particular, it is conceivable that, at this stage of the disease, two major 
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determinants may condition further clinical progression independently of the reduction of 
hepatocellular necrosis and inflammation induced by SVR. The first is represented by the 
remarkable hyperplasia of activated HSCs and myofibroblasts which is associated by a strong 
activation of anti-apoptotic pathways in these cells [68]. The second is due to the extensive 
changes in hepatic angioarchitecture as a consequence of neoangiogenesis and of the 
contraction of scar tissue leading to elevated tissue tension and are only minimally affected 
by the reduction of necroinflammation following SVR   [69, 70]. 
 
5. Methodological barriers to the development of anti-fibrotic agents for liver fibrosis 
 
The anatomical changes typical of the progression of chronic fibrogenic disorders of the liver 
and the progressive alteration, both in terms of topography and biochemistry, of the structure 
of the hepatic ECM stroma, represent the main barriers for drug delivery to target cells. 
Indeed, in advanced stages of the disease, irrespective of the aetiology of CLD, scar tissue is 
characterized by extensive collagen cross-linking, abundance of elastin, dense 
acellular/paucicellular ECM, and decreased expression and/or activity of specific 
metalloproteinases [71, 72].  In these conditions, independently of the cellular or molecular 
target of the drug under evaluation, the biochemical changes of the ECM and the vascular 
disconnection of large areas of the fibrotic tissue constitute a major and almost impenetrable 
physical barrier and definitely need to be considered when the end point of a proposed 
treatment is the reduction of fibrosis in a cirrhotic liver (if not the reversal of cirrhosis!).  
Another important aspect to be considered when addressing the reversibility of fibrosis and 
cirrhosis in human CLD (as opposed to animal models of liver fibrosis) is the long term 
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activation of HSC and their hyperplasia. Indeed, evidence obtained in studies employing 
freshly isolated vs. activated human HSC and human tissue samples indicates that established 
fibrotic tissue is characterized by a progressive resistance to apoptosis of HSC, leaving a critical 
mass of pro-fibrogenic cells refractory to reversion back to a quiescent state [68]. 
In any case, a crucial point to be always taken into account is the targeted pro-fibrogenic 
mechanism. Since the knowledge of the pathways possibly contributing to tissue scarring has 
grown exponentially as consequence of over 30 years of active research, there are several 
possible scenarios to be considered. The first scenario is provided by a treatment targeting a 
single cytokine shown to play a key pro-inflammatory and/or pro-fibrogenic role. In this case, 
the target (i.e. the cytokine itself or its receptors) is validated in a specific -/- animal model 
where the effect is almost inevitably an “all or nothing” effect. However, there is a very large 
probability that in the context of human fibrogenic diseases, developing in decades rather 
than weeks, the target cytokine is part of a pleiotropic network of mediators that will 
ultimately dilute the effects of its blockade. Indeed, the current way of thinking and validating 
potential targets constitutes a methodological barrier for the development of effective anti-
fibrogenic strategies per se. Along these lines, expectations on the efficacy of anti-fibrogenic 
agents are based on the adequacy of the targets identified as key mechanisms of fibrogenesis 
and on the results of in vitro studies and studies performed in experimental animal models. 
Accordingly, most of the failures of putative anti-fibrotic agents observed in the treatment of 
human disease are related to the large inadequacy of the pre-clinical platforms. In this 
context, the molecular mechanisms of liver fibrogenesis are largely investigated in cell culture 
of HSC (often murine and often immortalized cell lines rather than human primary cells) 
according to a “cell-centric” approach in which cell functions are analysed in the artificial 
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context of a 2D monolayer cell culture on plastic dishes. This prevents to take into 
consideration the key relationship between the fibrogenic cell itself and the surrounding 
diseased tissue microenvironment and in particular its 3D extracellular matrix biochemical 
structure and stiffness. Attempts to improve this methodological issue are currently in 
progress as described in detail in the article by Rombouts and Mazza published in this issue 
of Advanced Drug Delivery Reviews (add reference).  
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